Point-of-care molecular diagnosticsprimary
4 projects
Central to SMARTDIAGNOS (sepsis POC), PITBUL (TB POC with laser PCR), CORONADX (COVID-19 rapid diagnostics), and SPIDIA4P (pre-analytical standardization).
Organization
TATAA BIOCENTER AB
Swedish SME specializing in PCR-based molecular diagnostics, multi-omics biomarker validation, and point-of-care test development for health research consortia.
Technology SMEhealthSESME
H2020 projects
7
As coordinator
0
Total EC funding
€2.4M
Unique partners
70
What they do
Their core work
TATAA Biocenter is a Swedish SME specialized in molecular diagnostics, particularly PCR-based and multi-omics analytical services. They provide expertise in gene expression analysis, biomarker validation, and point-of-care diagnostic development for clinical and research applications. Their core contribution to EU projects lies in designing, optimizing, and validating molecular assays — from rapid infectious disease tests (TB, sepsis, COVID-19) to complex multi-omics profiling for chronic diseases like cancer and diabetes. They bridge the gap between laboratory-grade molecular biology and deployable diagnostic tools.
Core expertise
What they specialise in
PCR and qPCR technologyprimary
3 projects
PITBUL focused on ultra-fast laser PCR, SMARTDIAGNOS on next-gen sepsis diagnosis, and SPIDIA4P on standardizing pre-analytical workflows — all PCR-dependent.
Multi-omics profiling (proteomics & metabolomics)emerging
3 projects
PainFACT and OPTOMICS both involve proteomics and metabolomics for biomarker discovery; ELBA covers liquid biopsy analytics including circulating tumour DNA and exosomes.
Liquid biopsy and cancer biomarkerssecondary
2 projects
ELBA focused on circulating tumour cells, tumour-educated platelets, and extracellular vesicles; PainFACT includes biomarker genetics for comorbidity research.
Infectious disease diagnosticssecondary
3 projects
TB diagnostics (PITBUL), sepsis diagnosis (SMARTDIAGNOS), and COVID-19 rapid testing (CORONADX) cover bacterial, systemic, and viral infections respectively.
Evolution & trajectory
How they've shifted over time
Early focus
Rapid infectious disease POC diagnostics
Recent focus
Multi-omics chronic disease biomarkers
TATAA's early H2020 work (2016–2019) focused squarely on rapid point-of-care diagnostics for infectious diseases — sepsis, tuberculosis, and related POC instrument development using technologies like laser PCR. From 2020 onward, their focus shifted decisively toward multi-omics (proteomics, metabolomics) and biomarker-driven research for complex chronic conditions: cancer liquid biopsies, chronic pain comorbidities, diabetes, and cardiovascular disease. This evolution reflects a move from single-target rapid tests to systems-level molecular profiling for personalized medicine.
TATAA is moving from rapid single-pathogen testing toward complex multi-omics biomarker platforms for chronic and multifactorial diseases, positioning them for personalized medicine consortia.
Collaboration profile
How they like to work
Role: specialist_contributorReach: European23 countries collaborated
TATAA consistently joins as a specialist participant rather than leading projects — zero coordinator roles across all seven projects. They work in sizeable European consortia (70 unique partners across 23 countries), suggesting they are sought after as a technical service provider rather than a project architect. Their role as a third party in ELBA further confirms they operate as a specialized contributor brought in for specific molecular biology expertise.
TATAA has built a broad European network of 70 unique consortium partners spanning 23 countries, indicating they are a well-connected and trusted specialist despite their small size. Their network spans clinical, academic, and industrial partners across Western and Northern Europe.
Why partner with them
What sets them apart
TATAA occupies a rare niche as a commercially operating molecular diagnostics SME that bridges academic research and clinical application. Unlike university labs, they bring industrial-grade assay development and validation to consortia — a practical partner who can take a biomarker concept through to a standardized, reproducible test. Their dual competence in both rapid POC diagnostics and deep multi-omics profiling makes them unusually versatile for health-focused consortia needing molecular biology muscle.
Notable projects
Highlights from their portfolio
- PainFACTLargest single EC contribution (EUR 1.09M) and represents their strategic shift into multi-omics biomarker research for chronic pain and comorbidities.
- PITBULShowcases their core PCR expertise applied to ultra-fast laser PCR for tuberculosis — a technically distinctive point-of-care approach.
- CORONADXRapid mobilization for COVID-19 diagnostics demonstrates their ability to pivot quickly to urgent public health needs with POC testing expertise.
Cross-sector capabilities
Digital health and cloud-based diagnostic softwareManufacturing of point-of-care instrumentsFood safety and agricultural biomarker testingPharmaceutical biomarker validation
More in Health & Biomedical
See all Health & Biomedical organizations →KOBENHAVNS UNIVERSITET
Denmark's largest research university, excelling in genomics, CRISPR, microbiome science, ancient DNA, and climate research across 696 H2020 projects.
Open →
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France's national biomedical research agency — 400+ H2020 projects spanning neuroscience, infectious disease, cancer, and omics-driven diagnostics.
Open →
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany's leading research university in molecular biosciences and translational medicine, with 303 H2020 projects and exceptional ERC grant concentration.
Open →